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Results Figures
• Several variant histologic patterns of clear cell renal cell carcinoma 
(RCC) are well known, particularly sarcomatoid and rhabdoid features. 
• However, we have encountered rare cases in which a high-grade 
adenocarcinoma not otherwise specified (NOS) pattern or urothelial 
carcinoma-like component would be difficult to appreciate as clear cell 
RCC.
Conclusion
• Clear cell RCC with a poorly differentiated component resembling 
adenocarcinoma or urothelial carcinoma is a novel source of morphologic 
heterogeneity that has not been previously well characterized. 
• Potential pitfalls include decreased or absent CA-IX staining the high-
grade component and aberrant positivity for cytokeratin 7 or 20. 
• With the increasing use of renal mass biopsy and biopsies of metastatic 
sites for targeted therapy, pathologists should be aware of this entity and 
consider the possibility of clear cell RCC even for morphologically 
unusual tumors.
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• We retrieved 26 tumors with histologically typical clear cell RCC 
juxtaposed to a high-grade non-clear cell component.
• A high-grade non-clear cell component was defined as non-sarcomatoid, 
non-rhabdoid areas that would be difficult to assign as renal cell in origin 
if viewed in isolation.
• Tumors were studied with immunohistochemistry and fluorescence in 
situ hybridization (FISH) or sequencing.
• Median percentage of poorly differentiated component was 50% 
(IQR20-70). 
• All tumors showed abrupt transition from clear cell carcinoma to poorly-
differentiated areas, with micropapillary (7/26; 27%), urothelial-like 
(10/26; 39%), and adenocarcinoma NOS features (9/26; 35%). 
• Carbonic anhydrase IX (CA-IX) was uniformly positive in the well-
differentiated component (20/20), but the poorly differentiated 
component showed a median positivity of 82.5% (IQR 65-100). 
• The poorly differentiated component was positive for CK7 (5/19; 26%), 
CK20 (3/12; 25%), AMACR (7/12; 58%), PAX8 (12/15; 80%), and 
showed intact FH (6/6; 100%). CDX2 was uniformly negative. 
• Chromosome 3p loss or VHL mutation was present in 8/13 (62%), tested 
with either FISH (n = 9) or sequencing (n = 4). 
• All tested cases were negative for TFE3 (0/11) and TFEB (0/9) 
rearrangements using FISH. 
• With follow-up, 5/21 (24%) patients were alive with metastatic disease 
and 5/21 (24%) had died of disease on follow up. One metastasis with 
biopsy material was composed only of the poorly-differentiated 
component and was near-negative for CA-IX.
Age Sex Size Site Grade Stage Nodes Metastasis % clear cell / 
poorly-diff
TFE3
FISH
TFEB
FISH
VHL FISH or 
molecular
1 52 M 6.8 L 4 pT3a pN0 NA 40%/60% Negative Negative Deletion
2 70 F 15 R 4 pT4 pN0 AWD 80%/20% Negative Negative Deletion
3 76 M 6 R 4 pT3a pNX NA 70%/30% NA NA NA
4 59 M 5.8 R 4 pT1b pN0 AWD 70%/30% Negative Negative No deletion
5 64 M 5.5 L 4 pT1b pN0 NED 40%/60% Negative Negative No deletion
6 69 M 3.9 R 3 pT1a pNX AWD 30%/70% Negative Negative Deletion
7 65 F 15 R 4 ypT3a pNX NED 30%/70% Negative Negative No deletion
8 52 M 13 L 4 pT3a pNX NED 60%/40% Negative NA Deletion
9 51 M 4.7 R 3 pT3a pNX NA 90%/10% Negative Negative No deletion
10 61 M 6 L 3 pT3a pNX NA 20%/60% Negative Negative NA
11 61 F 6.6 L 4 pT3a pNX NA NA NA NA VHL mutation
12 61 M 13.1 R 4 pT3a pNX DOD 70%/30% Negative Negative No deletion
13 43 M 9.9 R 4 pT4 pN1 DOD 95%/5% NA NA NA
14 60 F 6.5 L 4 pT3b pN1 NED 20%/80% NA NA NA
15 65 M 6 R 4 pT3a pNX NED 30%/70% NA NA NA
16 56 M 14 L 4 pT3b pN0 NED 20%/80% NA NA NA
17 38 M 7.6 R 4 pT3a pNX DOD 30%/70% Negative NA NA
18 48 M 4.5 L 3 pT1b pN0 NED 80%/20% NA NA NA
19 37 M 10.8 R 4 pT2b pNX NED 80%/20% NA NA NA
20 41 M 16.2 L 3 pT3a pN1 DOD 60%/40% NA NA VHL mutation
21 73 F 9 L 3 pT3a pN1 DOD 40%/60% NA NA VHL mutation
22 62 F 14.6 L 4 pT3 pN1 DOOC 20%/80% NA NA NA
23 68 F 5.5 R 4 pT1b pN1 NA 20%/80% NA NA NA
24 54 M 22 L 4 pT3 pN1 AWD 95%/5% NA NA NA
25 47 M 11.3 L 4 pT3 pN1 NA 10%/90% NA NA NA
26 58 M 8.7 L 4 pT3 pN1 AWD 90%/10% NA NA VHL mutation
Design
Background
Results
CAIX - clear cell / poorly 
differentiated RCC PAX8 CK7 AMACR CK20 Other
1 100%/40% 0% 0% 0% 0% intact FH
2 80%/50% 0% 0% NA 0% intact FH
3 NA NA NA NA NA
4 80%/80% 90%/70% 0%/0% 0/0% 0%/0%
5 100%/100% 10%/10% 0%/0% 100%/80% 0%/0%
6 100%/100% 40%/70% 0%/10% 100%/100% 0%
7 100%/80% 0%/20% 0% 0% 0%/60%
8 100%/100% 20%/95% 0%/0% 80%/50% 0%/0% CD10+, Vimentin+ 
9 100%/100% 100%/100% 5%/0% 0/70% weak <5%/0% Vimentin+, CD10+, Melan negative 
10 100%/70% NA 15% 100% 0%
11 100%/100% 100%/100% 0%/0% NA 0/90% RCC 90%, INI retained, CD10+
12 85%/85% 0% 0% 0 0 EMA+, AE1/3+, CD10+, vimentin+
13 75%/70% NA 0 NA 15% Vimentin+, Cam5.2, CD10+
14 100%/50% NA NA NA NA Vimentin+
15 NA NA NA NA NA
16 100%/100% NA 0 NA NA
17 100%/20% 100% 0 NA NA
18 100%/100% 100% NA NA NA
19 NA 100% NA NA NA
20 90%/70% weaker 100% 0%/15% 80%/100% NA
21 100%/100% 100% 0%/70% NA NA
22 NA NA NA NA NA
23 NA NA NA NA NA
24 NA NA NA NA NA
25 100%/0% NA 0%/0% NA NA Vimentin+
26 100%/0% NA 0%/0% 100%/100% NA
Table 2: Immunohistochemistry
Table 1: Clinicopathological features
Figure 1: The tumor from patient 7 demonstrated poorly-differentiated, urothelial carcinoma-like 
morphology (A) with abrupt transition to conventional clear cell features (B, top). Cytokeratin 20 was 
substantially positive in the poorly-differentiated component (bottom, C) and CA-IX was markedly 
decreased to negative in these areas (D). A metastatic lesion involving the jaw was composed only of 
the poorly-differentiated component (E) and was negative for CA-IX but positive for PAX8 (F).
